What are monoclonal antibodies? Why do we need it in addition to the vaccine?

 When President Trump was diagnosed with COVID-19, one of the most recent experimental treatments he received was a combination of monoclonal antibodies. But a vaccine may soon become available, so are other treatments necessary or helpful? What are monoclonal antibodies, in particular?

Over the past few months, people have learned about the various treatments used to fight COVID-19.

The anti-virus creamdisifir contributes to inhibiting the proliferation of viruses in human cells, and the plasma from the blood of donors recovering from Covid-19 may contain antibodies that suppress the virus and inflammation, and steroids such as dexamethasone work to change and reduce the serious inflammatory damage affecting the lungs, which leads to slowing failure Respiratory system.

The Food and Drug Administration has issued clearance for the approval of a monoclonal antibody drug for Eli Lilly called mlanifemab in emergency cases, and Regeneron is awaiting the green light from the FDA to approve its antibody treatment.

Monoclonal antibodies appear particularly promising in the treatment of their ability to neutralize the SARS-CoV-2 virus that causes Covid-19 disease and block its ability to infect a cell. This could be a life-saving intervention for people who are not able to generate a strong immune response to this virus, such as those over the age of 65, or who have health conditions that make them more vulnerable.

Even when a COVID-19 vaccine becomes available, monoclonal antibody therapy will play a role in controlling the epidemic.

What monoclonal antibodies and did not we need in addition to the vaccine - experimental treatments that people with Covid-19 received - inhibiting the reproduction of viruses in human cells

Why should we care?

The world must adopt other immunizations in its fight against the Covid-19 pandemic until a large proportion of people obtain immunity against infectious diseases, either through a vaccine or the absolute spread in society.

In addition to the previously mentioned treatments, monoclonal antibodies can provide another means of eliminating the virus as soon as an infection occurs.

These manmade antibodies offer the world the possibility of immunotherapy similar to using recovered plasma but with a more targeted and accurate procedure.

Although the vaccine will contribute to protecting the general public in the end, the vaccination will not be immediate until the vaccine reaches 100% of the population, in addition to our lack of knowledge of its effectiveness. In addition, the effect of the vaccine is not immediate, and it will take several weeks to obtain a strong antibody response, and in the meantime, monoclonal antibodies may contribute to eliminating the virus replicating in the body.

antibody

An antibody is a Y-shaped protein that the immune system naturally produces in our bodies to target any foreign body or whatever is not part of the body. These foreign bodies are called antigen and can be found in allergens, bacteria, viruses, as well as other things such as toxins or transplanted organs.

Monoclonal antibody therapy mimics the body's natural immune response and targets foreign substances such as viruses that infect and harm people. There are also monoclonal antibodies that drug companies have created to target cancer cells.

Monoclonal antibodies are one of the most powerful types of drugs, and in 2019, monoclonal antibodies were ranked seventh among the ten best-selling drugs.

Regarding President Trump, the experimental treatment provided by the drug company Regeneron included two antibodies.

The spinal protein on the Coronavirus usually fits perfectly with the receptor for the angiotensin converting enzyme 2 on human cells, and it is a protein that is widespread in lung cells and other organs, and when this connection occurs, the virus is able to infect cells and multiply within them. Monoclonal antibodies may slow or stop infection by binding to the viral spinal protein before it reaches the ACE receptor. 

How do monoclonal antibodies form?

The manufacturing and production process of the monoclonal antibodies that eliminate the Corona virus is complex, as it must be made inside cells taken from hamster ovaries and cultivated in giant steel tanks, and then the antibodies made by these cells are extracted and purified. Unfortunately, these monoclonal antibodies that have been used to treat other diseases for years are often expensive.

The two antibodies produced by Regeneron targeted the spinal protein of SARS-Cove-2, as the protrusions on the surface of the virus give it a crown-like appearance, which is of great importance for infecting human cells.

One of the two Regeneron antibodies is a replica or clone of an antibody extracted from a person who has recovered from COVID-19. When the mouse was injected with spinal protein, its human immune system produced antibodies, after which it extracted the mouse's most effective antibody and was used to form part of this treatment.

Eli Lilly monoclonal antibody treatment was determined with Pamlanifemab from a blood sample taken from a person who was among the first to recover from Covid-19.

Both companies have a large-scale industry with strong global supply chains for the production of monoclonal antibodies, as well as the establishment of several global manufacturing sites to increase the level of supply. Eli Lilly has received FDA approval, Regeneron is still awaiting approval, and unfortunately there will be a shortage of antibodies after approval.

Monoclonal antibody in addition to the vaccine

The monoclonal antibodies will provide rapid protection against infection, complementing the work of the vaccines. When given to individuals, monoclonal antibodies will contribute to providing immediate protection that extends from weeks to months, as vaccines take longer to provide protection because they must confront the immune system, but the advantage of vaccines is that they usually provide long-term protection.

Regeneron and Eli Lily products are injected intravenously, after which the patient must be observed. As they provide immediate protection, the implications for treating or protecting high-risk groups are enormous.

These drugs have the potential to treat infected people and may prevent primary health care workers and public health care professionals in the ranks of the epidemic response. Monoclonal antibodies may also be beneficial for the elderly, young children, and immunocompromised people that vaccines do not work for or could be dangerous for them.